---
title: "Huntsman Corporation Stock 12‑Month Price Target Cut to $14, Implies 32% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291458582.md"
description: "Huntsman Corporation's 12-month average price target was cut to $14 from $14.15, based on estimates from 13 analysts with forecasts ranging from $11 to $18. At the June 30 closing price, this implies a 32% upside potential. The consensus rating remains 'Hold' among 16 covering analysts, comprising 3 Buys, 11 Holds, and 2 Sells."
datetime: "2026-07-01T20:20:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291458582.md)
  - [en](https://longbridge.com/en/news/291458582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291458582.md)
generator: "portal-rs"
---

# Huntsman Corporation Stock 12‑Month Price Target Cut to $14, Implies 32% Upside

-   According to estimates from 13 analysts, Huntsman Corporation stock's average price target has fallen from $14.15 to $14, with forecasts ranging from $11 to $18 per share
-   Based on the Jun. 30 closing price, the updated target implies approximately 32% potential upside
-   Consensus rating remains at “Hold” across 16 covering analysts, with 3 Buys, 11 Holds and 2 Sells

Explore more price target data and ratings for Huntsman Corporation on the , and track all previous and future analyst recommendations for Huntsman Corporation in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [HUN.US](https://longbridge.com/en/quote/HUN.US.md)

## Related News & Research

- [Huntsman, Olin supplement merger proxy disclosures after shareholder lawsuits, demand letters](https://longbridge.com/en/news/296209844.md)
- [Top Executive Makes Bold Insider Move on Huntsman Stock](https://longbridge.com/en/news/294768527.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)
- [Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales](https://longbridge.com/en/news/296529363.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**